MA31000B1 - Derives 2-aza-bicyclo[3.1.0]hexane - Google Patents

Derives 2-aza-bicyclo[3.1.0]hexane

Info

Publication number
MA31000B1
MA31000B1 MA32004A MA32004A MA31000B1 MA 31000 B1 MA31000 B1 MA 31000B1 MA 32004 A MA32004 A MA 32004A MA 32004 A MA32004 A MA 32004A MA 31000 B1 MA31000 B1 MA 31000B1
Authority
MA
Morocco
Prior art keywords
aza
bicyclo
hexane
derivatives
compounds
Prior art date
Application number
MA32004A
Other languages
English (en)
French (fr)
Inventor
Hamed Aissaoui
Christoph Boss
Markus Gude
Ralf Koberstein
Thierry Sifferlen
Daniel Trachsel
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA31000B1 publication Critical patent/MA31000B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
MA32004A 2006-12-28 2009-06-17 Derives 2-aza-bicyclo[3.1.0]hexane MA31000B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2006055042 2006-12-28

Publications (1)

Publication Number Publication Date
MA31000B1 true MA31000B1 (fr) 2009-12-01

Family

ID=39343649

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32004A MA31000B1 (fr) 2006-12-28 2009-06-17 Derives 2-aza-bicyclo[3.1.0]hexane

Country Status (28)

Country Link
US (1) US8288435B2 (index.php)
EP (1) EP2094690B1 (index.php)
JP (1) JP2010514751A (index.php)
KR (1) KR20090094168A (index.php)
CN (1) CN101568536B (index.php)
AR (1) AR064561A1 (index.php)
AT (1) ATE505467T1 (index.php)
AU (1) AU2007340944B2 (index.php)
BR (1) BRPI0720876A2 (index.php)
CA (1) CA2669821A1 (index.php)
CL (1) CL2007003827A1 (index.php)
CY (1) CY1111705T1 (index.php)
DE (1) DE602007013937D1 (index.php)
DK (1) DK2094690T3 (index.php)
ES (1) ES2364297T3 (index.php)
HR (1) HRP20110509T1 (index.php)
MA (1) MA31000B1 (index.php)
MX (1) MX2009006860A (index.php)
MY (1) MY157344A (index.php)
NO (1) NO20092762L (index.php)
NZ (1) NZ578642A (index.php)
PL (1) PL2094690T3 (index.php)
PT (1) PT2094690E (index.php)
RU (1) RU2460732C2 (index.php)
SI (1) SI2094690T1 (index.php)
TW (1) TW200833328A (index.php)
WO (1) WO2008081399A2 (index.php)
ZA (1) ZA200905229B (index.php)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101522618A (zh) * 2006-09-29 2009-09-02 埃科特莱茵药品有限公司 3-氮杂-双环[3.1.0]己烷衍生物
CN101568533A (zh) 2006-12-01 2009-10-28 埃科特莱茵药品有限公司 3-异芳基(氨基或酰胺基)-1-(联苯或苯基噻唑基)羰基哌啶衍生物食欲素受体抑制剂
CL2008000836A1 (es) * 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
WO2009040730A2 (en) * 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
BRPI0908096A2 (pt) * 2008-02-21 2015-08-25 Actelion Pharmaceuticals Ltd Derivado de 2-aza-biciclo [2.2.1] heptano
CN102015645B (zh) * 2008-04-30 2012-11-14 埃科特莱茵药品有限公司 哌啶和吡咯烷化合物
EP2334643A1 (en) * 2008-10-14 2011-06-22 Actelion Pharmaceuticals Ltd. Phenethylamide derivatives and their heterocyclic analogues
EP2275421A1 (en) * 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
DK2519514T3 (en) * 2009-12-29 2015-11-16 Suven Life Sciences Ltd Neuronal nicotinic alpha4beta2-acetylcholine receptor ligands
AR083060A1 (es) * 2010-09-22 2013-01-30 Eisai R&D Man Co Ltd Compuesto de ciclopropano y composiciones farmaceuticas que lo contienen
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
ITMI20112329A1 (it) * 2011-12-21 2013-06-22 Rottapharm Spa Nuovi derivati spiro amminici
CN104220065A (zh) 2012-02-07 2014-12-17 Eolas治疗公司 取代的脯氨酸/哌啶用作食欲素受体拮抗剂
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
ITMI20120424A1 (it) * 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
ES2617863T3 (es) * 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
BR112015001201B1 (pt) * 2012-07-18 2022-02-22 University Of Notre Dame Du Lac Compostos anti-infecciosos 5,5-heteroaromáticos e composição
US9493446B2 (en) 2012-10-10 2016-11-15 Actelion Pharmaceuticals Ltd. Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
TWI664177B (zh) 2013-12-03 2019-07-01 瑞士商愛杜西亞製藥有限公司 晶形
EA029725B1 (ru) 2013-12-04 2018-05-31 Идорсиа Фармасьютиклз Лтд Применение производных бензимидазолпролина
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
EP3180332B1 (en) 2014-08-13 2021-10-27 Eolas Therapeutics Inc. Difluoropyrrolidines as orexin receptor modulators
BR112017004742B1 (pt) 2014-09-11 2022-11-29 Janssen Pharmaceutica Nv 2-azabiciclos substituídos e seu uso como moduladores de receptor de orexina
US10188652B2 (en) 2014-10-23 2019-01-29 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
CN106588900A (zh) * 2015-10-20 2017-04-26 北京康辰医药科技有限公司 一种苯并双环化合物或其药学上可接受的盐、药物组合物及其应用
WO2017139603A1 (en) 2016-02-12 2017-08-17 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
WO2017144015A1 (zh) * 2016-02-26 2017-08-31 江苏恒瑞医药股份有限公司 一种新毒素及其中间体的制备方法
US20190151304A1 (en) 2016-05-10 2019-05-23 Inserm (Institut National De La Santé Et De La Rechercjae Médicale Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory
LT3619199T (lt) 2017-05-03 2021-09-27 Idorsia Pharmaceuticals Ltd 2-([1,2,3]triazol-2-il)-benzenkarboksirūgšties darinių gamyba
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
MX2023001818A (es) 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
AU2021360172A1 (en) 2020-10-13 2023-03-30 Boehringer Ingelheim International Gmbh Process of reworking
CN116783182B (zh) * 2021-02-02 2025-08-29 南京明德新药研发有限公司 四氢吡咯并环化合物及其应用
TW202400149A (zh) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621126A5 (index.php) 1974-02-07 1981-01-15 Plantex Ltd
EP0757692A1 (en) 1994-04-29 1997-02-12 PHARMACIA & UPJOHN COMPANY Methanol derivatives for treatment of retroviral infections especially hiv infections
WO2001096302A1 (en) 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines for use as orexin receptor antagonists
US6696443B2 (en) 2000-11-20 2004-02-24 Scios, Inc. Piperidine/piperazine-type inhibitors of p38 kinase
DE60108420T2 (de) 2000-11-28 2005-12-22 Smithkline Beecham P.L.C., Brentford Morpholinderivate als antagonisten an orexinrezeptoren
WO2002089800A2 (en) * 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
IL158463A0 (en) * 2001-05-05 2004-05-12 Smithkline Beecham Plc N-aroyl cyclic amines
GB0111341D0 (en) 2001-05-10 2001-07-04 Bp Chem Int Ltd Novel polymerisation catalysts
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
US7470710B2 (en) 2001-06-28 2008-12-30 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0124463D0 (en) * 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Compounds
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
ES2273083T3 (es) * 2002-09-18 2007-05-01 Glaxo Group Limited N-aroilaminas ciclicas como antagonistas de los receptores de orexina.
GB0225884D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
CA2518945A1 (en) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
US7538109B2 (en) * 2003-04-28 2009-05-26 Actelion Pharmaceuticals Ltd Quinoxalin-3-one derivatives as orexin receptor antagonists
BRPI0508263B8 (pt) * 2004-03-01 2021-05-25 Idorsia Pharmaceuticals Ltd derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
DE602007012910D1 (de) * 2006-08-15 2011-04-14 Actelion Pharmaceuticals Ltd Azetidinverbindungen als orexin-rezeptor-antagonisten
CN101522618A (zh) * 2006-09-29 2009-09-02 埃科特莱茵药品有限公司 3-氮杂-双环[3.1.0]己烷衍生物
CN101568533A (zh) * 2006-12-01 2009-10-28 埃科特莱茵药品有限公司 3-异芳基(氨基或酰胺基)-1-(联苯或苯基噻唑基)羰基哌啶衍生物食欲素受体抑制剂
CL2008000836A1 (es) * 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
EP2155739B1 (en) * 2007-05-14 2010-10-06 Actelion Pharmaceuticals Ltd. 2-cyclopropyl-thiazole derivatives
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
WO2008147518A1 (en) 2007-05-23 2008-12-04 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
CA2691373A1 (en) 2007-07-03 2009-01-08 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.3.0]octane compounds
AR067665A1 (es) 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
CN101874028B (zh) * 2007-07-27 2012-11-14 埃科特莱茵药品有限公司 2-氮杂-二环[3.3.0]辛烷衍生物
WO2009040730A2 (en) * 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
BRPI0908096A2 (pt) * 2008-02-21 2015-08-25 Actelion Pharmaceuticals Ltd Derivado de 2-aza-biciclo [2.2.1] heptano
CN102015645B (zh) * 2008-04-30 2012-11-14 埃科特莱茵药品有限公司 哌啶和吡咯烷化合物
TW200940822A (en) * 2009-05-07 2009-10-01 Wan Chi Steel Ind Co Ltd Water wheel mechanism with sun-and-planet type blade

Also Published As

Publication number Publication date
TW200833328A (en) 2008-08-16
BRPI0720876A2 (pt) 2014-03-04
RU2460732C2 (ru) 2012-09-10
RU2009128739A (ru) 2011-02-10
EP2094690A2 (en) 2009-09-02
ES2364297T3 (es) 2011-08-30
CN101568536B (zh) 2011-12-28
NO20092762L (no) 2009-07-27
HRP20110509T1 (hr) 2011-08-31
CA2669821A1 (en) 2008-07-10
KR20090094168A (ko) 2009-09-03
AU2007340944B2 (en) 2013-04-18
WO2008081399A2 (en) 2008-07-10
MY157344A (en) 2016-05-31
SI2094690T1 (sl) 2011-07-29
ZA200905229B (en) 2010-10-27
ATE505467T1 (de) 2011-04-15
US20110124636A1 (en) 2011-05-26
PL2094690T3 (pl) 2011-09-30
PT2094690E (pt) 2011-07-08
AR064561A1 (es) 2009-04-08
DK2094690T3 (da) 2011-07-18
WO2008081399A3 (en) 2008-08-28
EP2094690B1 (en) 2011-04-13
NZ578642A (en) 2012-01-12
JP2010514751A (ja) 2010-05-06
US8288435B2 (en) 2012-10-16
MX2009006860A (es) 2009-07-07
CL2007003827A1 (es) 2008-09-26
CY1111705T1 (el) 2015-10-07
DE602007013937D1 (de) 2011-05-26
HK1136554A1 (en) 2010-07-02
AU2007340944A1 (en) 2008-07-10
CN101568536A (zh) 2009-10-28

Similar Documents

Publication Publication Date Title
MA31000B1 (fr) Derives 2-aza-bicyclo[3.1.0]hexane
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
MA32151B1 (fr) Derives de 2-aza-bicyclo[2.2.1]heptane
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA31289B1 (fr) Derives de thiazolidine
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA30162B1 (fr) Nouveaux derives de pyrrole a cycles fusionnes
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA30427B1 (fr) Derives bicycliques utilises comme inhibiteurs de cetp
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
MA31580B1 (fr) Derives de bicyclolactames substitués
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
MA29393B1 (fr) Derives d'azole sous forme d'inhibiteurs de lipase et de phospholipase
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA27771A1 (fr) 5,7-diaminopyrazolo[4,3-d]pyrimidines utiles dans le traitement de l'hypertension
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
MA31766B1 (fr) Composés organiques
MA30765B1 (fr) Derives innovants du thiophene
BRPI0413973A (pt) compostos
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.